TQA3605 tablets

DRUG3 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Chronic Hepatitis BChronic Hepatitis b

Phase 1

A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B

Active, not recruitingNCT06150014

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chronic Hepatitis b

Start: 2023-12-07End: 2026-09-30Updated: 2024-11-14

Phase 2

A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects

WithdrawnNCT06990776

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chronic Hepatitis B

Start: 2025-07-09End: 2025-07-17Updated: 2025-08-03

Phase 3

Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response

Not yet recruitingNCT07797231

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chronic Hepatitis B

Start: 2026-09-01End: 2029-10-01Target: 930Updated: 2026-09-03